Baxter Pharma India sets up global Pharmaceuticals RnD Centre in Ahmedabad

Commenting on the occasion, Alok Sonig, President, Pharmaceuticals, Baxter International Inc. said, "Our world-class Ahmedabad R&D Centre is critical to unleashing the full power of our Pharmaceuticals pipeline and helping us advance patient care worldwide through differentiated injectable products to be commercialized globally."

The 20,500-square-foot, state-of-the-art R&D Centre features an array of sophisticated equipment and research labs that will focus on pharmaceutical product development and capabilities in therapeutic areas such as critical care, analgesic, renal, cardiovascular anesthesia, anti-infective and antipyretic. It will support Baxter's global manufacturing facilities, including those in Ahmedabad, Germany, Ireland, Italy, and the United States, among others.

This Pharmaceuticals R&D Centre is part of Baxter's network of more than 25 global R&D centers, including 4 in the APAC region.

"The COVID-19 pandemic has further highlighted the critical importance of increasing access to healthcare and providing affordable, quality medicines. Our team in India, particularly those working in the Ahmedabad Pharmaceuticals R&D Centre, will play an integral role in advancing our pipeline, expanding our products to new markets, and innovating to continue responding to the needs of patients all over the world," said Dr. Mahesh Chaubal, Vice President, Pharmaceuticals R&D, Baxter International Inc.

Dr. Sanju Dhawan, Director - R&D, Baxter Pharmaceuticals India Pvt. Ltd. Ahmedabad, said, "This R&D expansion broadens our presence in India while also acknowledging the country's specialised capabilities and potential. We are delighted with the diverse pool of talent that the Pharmaceuticals R&D Centre has, and we anticipate that it will attract even more talented professionals in the near future. This Centre is indeed a significant step forward to achieve our mission to save and sustain lives by meeting the unmet needs of patients in India and throughout the world through innovation."

Read also: Baxter launches cardiovascular medicine Norepinephrine in premix formulation in US